- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07928089
Mechanisms Within the Autonomic Nervous SysTEm undeRlying MusIc Therapy's aNalgesic Effects in Sickle Cell Disease (MASTERMIND)
Sickle cell disease causes very painful episodes that can happen without warning. Pain is one of the biggest problems for people with SCD. Medicines like opioids can help, but they have serious side effects. Doctors are looking for other ways to treat pain.
Investigators have already found that music therapy - breathing exercises guided by a trained music therapist - can lower pain in adults with SCD. But investigators don't know exactly how it works yet inside the body.
This study will look at two possible reasons why music therapy helps:
- It may calm the body's "fight-or-flight" (sympathetic) nervous system, which can make pain worse when it is too active.
- It may boost the "calming" (parasympathetic) nervous system, which may ease pain and reduce inflammation.
- It may lower swelling and inflammation in the body, which also drives pain.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Kaitlyn Super
- Telefoonnummer: 216-844-1800
- E-mail: kaitlyn.super@uhhospitals.org
Studie Locaties
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- University Hospitals
-
Contact:
- Kaitlyn Super
- Telefoonnummer: 216-844-1800
- E-mail: kaitlyn.super@uhhospitals.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- (1) are age ≥18 years
- (2) have a diagnosis of SCD documented in the electronic health record (EHR)--- (3) meet Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy (AAPT) criteria for chronic SCD pain
- (4) are able to speak and understand English
- (5) have an email address and access to a mobile device with a functioning data plan (to get pain diaries)
- (6) report that pain interfered with daily activities at least 1-2 days in past week will be eligible for the study. -
Exclusion Criteria:
- (1) have < 3 vaso-occlusive crises (VOCs) per year and no VOCs in the past 3 months
- (2) have significant visual, hearing, psychiatric or cognitive impairment
- (3) are currently engaged in mind-body therapies under the supervision of a healthcare professional specifically for pain management
- (4) have a planned major medical event in next 8 weeks (e.g., childbirth, orthopedic surgery, gene therapy, stem cell transplant) that does not include routine disease modifying therapies (e.g., blood transfusions)
- (5) are unable or unwilling to refrain from stopping all medications that interfere with the autonomic nervous system for 5 half-lives prior to autonomic testing and from changing their medication regimen during the 2 weeks that separate autonomic testings and blood draws
- (6) develop active VOC requiring hospitalization at enrollment
- (7) have conditions that would significantly affect autonomic testing interpretation, such as severe arrhythmias or pregnancy, will be excluded from the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Music Therapy
The MT-BC will engage the participant in a 20-minute deep breathing exercise with live music beating at a defined tempo. Participants will repeat this session on their own. |
Participants will undergo a 20-minute music therapy session with a board certified music therapist, then will repeat this on their own once daily for 2 weeks. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in electrodermal activity (EDA) as measured by change in electrical potential at the surface of the skin
Tijdsspanne: Baseline and after 2 weeks
|
Lower EDA reflects less sympathetic tone |
Baseline and after 2 weeks
|
|
Change in Quantitative Sudomotor Axon Reflex Test (QSART) as measured by sweat output values
Tijdsspanne: Baseline and after 2 weeks
|
Lower QSART values reflect less sympathetic activity |
Baseline and after 2 weeks
|
|
Changes in Pupillometry parameters as measured by constriction velocity
Tijdsspanne: Baseline and after 2 weeks
|
Faster constriction velocity indicates a higher pupillary vagal tone. |
Baseline and after 2 weeks
|
|
Changes in Pupillometry parameters as measured by percent reflex amplitude
Tijdsspanne: Baseline and after 2 weeks
|
Larger percentage of reflex amplitude indicates higher pupillary vagal tone. |
Baseline and after 2 weeks
|
|
Changes in Pupillometry parameters as measured by dilation velocity.
Tijdsspanne: Baseline and after 2 weeks.
|
Slower dilation velocity indicates lower pupillary sympathetic tone. |
Baseline and after 2 weeks.
|
|
Change in Heart Rate Response to deep breathing
Tijdsspanne: Baseline and after 2 weeks
|
Increased heart rate response to deep breathing denotes increased cardiovagal tone. |
Baseline and after 2 weeks
|
|
Measurement of average supine resting Blood Pressure (BP)
Tijdsspanne: Baseline and after 2 weeks
|
Lower average resting BP denote lower cardiac sympathetic tone |
Baseline and after 2 weeks
|
|
Measurement of average supine resting Heart Rate (HR)
Tijdsspanne: Baseline and after 2 weeks
|
Lower average resting HR denote lower cardiac sympathetic tone |
Baseline and after 2 weeks
|
|
Change in supine resting respiratory rate
Tijdsspanne: Baseline and after 2 weeks
|
A lower resting respiratory rate reflects a shift of autonomic balance toward parasympathetic (vagal) dominance with reduced central sympathetic outflow. |
Baseline and after 2 weeks
|
|
Change in the maximum heart rate during the Valsalva maneuver
Tijdsspanne: Baseline and after 2 weeks
|
An increased Valsalva Ratio (maximum heart rate to the minimum heart rate) reflects an increase in cardiac parasympathetic tone. |
Baseline and after 2 weeks
|
|
Change in the minimum heart rate shortly after the Valsalva maneuver
Tijdsspanne: Baseline and after 2 weeks
|
An increased Valsalva Ratio (maximum heart rate to the minimum heart rate) reflects an increase in cardiac parasympathetic tone. |
Baseline and after 2 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in C Reactive Protein as measured by bloodwork
Tijdsspanne: Baseline and after 2 weeks
|
Lower levels of CRP indicate lower levels of inflammation |
Baseline and after 2 weeks
|
|
Change in Cytokine levels as measured by bloodwork
Tijdsspanne: Baseline and after 2 weeks
|
Lower levels of cytokines indicate lower levels of inflammation |
Baseline and after 2 weeks
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pain intensity changes as measured by the Visual Analog Scale (VAS)
Tijdsspanne: Baseline and after 2 weeks of daily music therapy
|
The VAS is a straight 100 mm line-usually horizontal-with descriptive word anchors at each end representing opposite extremes of a subjective experience, such as 0 being "no pain" and 10 being "worst possible pain". |
Baseline and after 2 weeks of daily music therapy
|
|
Pain intensity changes as measured by the Brief Pain Inventory (BPI)
Tijdsspanne: Baseline and after 2 weeks of daily music therapy
|
Brief Pain Inventory (BPI) is a self-administered questionnaire used to evaluate pain severity and how pain interferes with daily life on scales from 0 to 10, with 0 being no pain, and 10 being severe pain. |
Baseline and after 2 weeks of daily music therapy
|
|
Pain diaries
Tijdsspanne: Daily for 2 weeks
|
Daily pain intensity and analgesic use |
Daily for 2 weeks
|
|
Music therapy adherence
Tijdsspanne: Daily for 2 weeks
|
Daily log of adherence to the home-based music therapy protocol |
Daily for 2 weeks
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Kamal R Chémali, MD, University Hospitals
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Pathologische processen
- Genetische ziekten, aangeboren
- Hematologische ziekten
- Bloedarmoede, hemolytisch, aangeboren
- Bloedarmoede, hemolytisch
- Bloedarmoede
- Hemoglobinopathieën
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Hemische en lymfatische ziekten
- Pijn
- Ontsteking
- Bloedarmoede, sikkelcel
- Therapeutica
- Complementaire therapieën
- Patiëntenzorg
- Psychotherapie
- Gedragsdisciplines en activiteiten
- Revalidatie
- Nazorg
- Continuïteit van patiëntenzorg
- Zintuiglijke kunsttherapieën
- Muziektherapie
Andere studie-ID-nummers
- STUDY20260271
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .